This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Montalescot, G. Articles by Zapol, W. M. Search for Related Content PubMed PubMed Citation Articles by Montalescot, G. Articles by Zapol, W. M.

Circulation, Vol 82, 1765-1777, Copyright © 1990 by American Heart Association

ARTICLES

Thromboxane receptor blockade prevents pulmonary hypertension induced by heparin-protamine reactions in awake sheep

G Montalescot, E Lowenstein, ML Ogletree, EM Greene, DR Robinson, K Hartl and WM Zapol
Department of Anesthesia, Massachusetts General Hospital, Boston 02114.

We used competitive thromboxane A2-prostaglandin endoperoxide receptor blockade (SQ 30,741) as a probe to evaluate the role of thromboxane in ovine pulmonary vasoconstriction associated with protamine reversal of heparin anticoagulation. Control heparin-protamine reactions induced rapid release of thromboxane into arterial plasma (more than 1 ng/ml plasma), a 2.5-fold increase of pulmonary artery pressure, a 20% decrease of PaO2, and a 30% reduction in arterial white blood cell concentration. After giving SQ 30,741 despite similar thromboxane release into arterial plasma after heparin-protamine challenge, acute pulmonary hypertension was significantly reduced when 94% of pulmonary vascular smooth muscle thromboxane receptors were occupied with SQ 30,741 (p less than 0.01 at 1 minute after protamine versus control heparin-protamine reaction) and was completely abolished by a 10 mg/kg i.v. bolus (p less than 0.0001 at 1 minute after protamine versus control). Peripheral leukopenia was not affected by SQ 30,741 prophylaxis, but hypoxemia was prevented. We conclude that thromboxane causes pulmonary vasoconstriction in ovine heparin-protamine-induced pulmonary hypertension. Pulmonary vasoconstriction and hypoxemia can be completely prevented by thromboxane receptor blockade.

This article has been cited by other articles:

				X. Ding and P. A. Murray Cellular mechanisms of thromboxane A2-mediated contraction in pulmonary veins Am J Physiol Lung Cell Mol Physiol, November 1, 2005; 289(5): L825 - L833. [Abstract] [Full Text] [PDF]

				A. Cogolludo, L. Moreno, F. Lodi, J. Tamargo, and F. Perez-Vizcaino Postnatal maturational shift from PKC{zeta} and voltage-gated K+ channels to RhoA/Rho kinase in pulmonary vasoconstriction Cardiovasc Res, April 1, 2005; 66(1): 84 - 93. [Abstract] [Full Text] [PDF]

				A. Cogolludo, L. Moreno, L. Bosca, J. Tamargo, and F. Perez-Vizcaino Thromboxane A2-Induced Inhibition of Voltage-Gated K+ Channels and Pulmonary Vasoconstriction: Role of Protein Kinase C{zeta} Circ. Res., October 3, 2003; 93(7): 656 - 663. [Abstract] [Full Text] [PDF]

				S. Archer and S. Rich Primary Pulmonary Hypertension : A Vascular Biology and Translational Research "Work in Progress" Circulation, November 28, 2000; 102(22): 2781 - 2791. [Abstract] [Full Text] [PDF]

				Q. Zhou, Y. Lai, H. Wei, R. Song, Y. Wu, and H. Zhang Unidirectional Valve Patch for Repair of Cardiac Septal Defects With Pulmonary Hypertension Ann. Thorac. Surg., November 1, 1995; 60(5): 1245 - 1248. [Abstract] [Full Text]

				W. J. Smith, M. P. Murphy, R. F. Appleyard, R. J. Rizzo, L. Aklog, R. G. Laurence, and L. H. Cohn Prevention of complement-induced pulmonary hypertension and improvement of right ventricular function by selective thromboxane receptor antagonism J. Thorac. Cardiovasc. Surg., March 1, 1994; 107(3): 800 - 806. [Abstract] [Full Text]